Order Article Reprints

Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, et al. Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers. 2020; 12(11):3427. https://doi.org/10.3390/cancers12113427

Matsuki, Takashi, Isaku Okamoto, Chihiro Fushimi, Hideaki Takahashi, Takuro Okada, Takahito Kondo, Hiroki Sato, Tatsuya Ito, Kunihiko Tokashiki, Kiyoaki Tsukahara, and et al. 2020. "Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients" Cancers 12, no. 11: 3427. https://doi.org/10.3390/cancers12113427

Matsuki, T., Okamoto, I., Fushimi, C., Takahashi, H., Okada, T., Kondo, T., Sato, H., Ito, T., Tokashiki, K., Tsukahara, K., Hanyu, K., Masubuchi, T., Tada, Y., Miura, K., Omura, G., Sawabe, M., Kawakita, D., & Yamashita, T. (2020). Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers, 12(11), 3427. https://doi.org/10.3390/cancers12113427